[1]江慧娟,庞东渤.视网膜光凝联合玻璃体内注射雷珠单抗治疗缺血型视网膜分支静脉阻塞（BRVO）致黄斑水肿的疗效[J].眼科新进展,2018,38(4):348-351.[doi:10.13389/j.cnki.rao.2018.0081]
　JIANG Hui-Juan,PANG Dong-Bo.Efficacy of intravitreal ranibizumab combined with laser photocoagulation for the treatment of macular edema induced by ischemic branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2018,38(4):348-351.[doi:10.13389/j.cnki.rao.2018.0081]
点击复制

视网膜光凝联合玻璃体内注射雷珠单抗治疗缺血型视网膜分支静脉阻塞（BRVO）致黄斑水肿的疗效/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
38卷
期数:
2018年4期
页码:
348-351
栏目:
应用研究
出版日期:
2018-04-05

文章信息/Info

Title:
Efficacy of intravitreal ranibizumab combined with laser photocoagulation for the treatment of macular edema induced by ischemic branch retinal vein occlusion
作者:
江慧娟; 庞东渤
121000　辽宁省锦州市，锦州医科大学
Author(s):
JIANG Hui-Juan; PANG Dong-Bo
Jinzhou Medical University，Jinzhou 121000，Liaoning Province，China
关键词:
视网膜分支静脉阻塞; 黄斑水肿; 雷珠单抗; 激光光凝
Keywords:
retinal branch vein occlusion; macular edema; ranibizumab; laser photocoagulation
分类号:
R774
DOI:
10.13389/j.cnki.rao.2018.0081
文献标志码:
A
摘要:
目的　观察视网膜光凝联合玻璃体内注射雷珠单抗治疗缺血型视网膜分支静脉阻塞（retinal branch vein occlusion，BRVO）致黄斑水肿的疗效。方法　选取在鞍山市中心医院眼科就诊的BRVO患者60例60眼，随机分为三组，20例行玻璃体内注射雷珠单抗治疗（A组）、20例行视网膜激光光凝治疗（B组）、20例行视网膜激光光凝联合玻璃体内注射雷珠单抗治疗（C组）。术前行最佳矫正视力（best corrected visual acuity，BCVA）、裂隙灯、眼底及眼压、眼底荧光血管造影（fundus fluorescein angiography，FFA）、光学相干断层扫描（optical coherence tomography，OCT）检查；术后第1天进行BCVA、裂隙灯及眼压检查；术后1个月、2个月、3个月分别行BCVA、裂隙灯、眼底及眼压检查，并利用OCT观察黄斑水肿。通过观察上述指标比较三组术后BCVA及黄斑中心凹厚度（central macular thickness，CMT）是否存在差异。结果　三组患者治疗后1个月、2个月、3个月BCVA较治疗前均有提高，差异均有统计学意义（均为P<0.05）。治疗后2个月、3个月，A组BCVA为0.26±0.14、0.26±0.14，优于B组的0.39±0.10、0.40±0.10，差异均有统计学意义（均为P<0.05）。治疗后3个月，C组BCVA为0.14±0.11，优于A组0.26±0.14，差异有统计学意义（P<0.05）。治疗后1个月、2个月、3个月，C组BCVA为0.30±0.13、0.20±0.12、0.14±0.11，优于B组0.43±0.10、0.39±0.10、0.40±0.10，差异均有统计学意义（均为P<0.05）。三组患者治疗后1个月、2个月、3个月CMT较治疗前均有提高，差异均有统计学意义（均为P<0.05）。治疗后1个月、2个月、3个月，C组CMT为（318.85±71.48）μm、（287.15±56.71）μm、（255.05±60.90）μm，优于A组（347.00±67.59）μm、（305.10±47.44）μm、（282.40±36.26）μm和B组（417.05±63.94）μm、（394.80±57.18）μm、（375.90±55.10）μm，差异均有统计学意义（均为P<0.05）。治疗后2个月、3个月，A组CMT优于B组，差异均有统计学意义（均为P<0.05）。结论　视网膜激光光凝联合玻璃体内注射雷珠单抗治疗BRVO致黄斑水肿疗效较好，效果优于单纯视网膜激光光凝或单纯玻璃体内注射雷珠单抗。
Abstract:
Objective　To observe the therapeutic efficacy of intravitreal ranibizumab combined with laser photocoagulation for the treatment of macular edema associated with ischemic branch retinal vein occlusion (BRVO).Methods　Together 60 patients (60 eyes) with BRVO in Anshan City Central Hospital were included and divided into three groups，20 patients with intravitreal ranibizumab treatment as A group，20 patients with retinal laser photocoagulation treatment as B group，and another 20 patients with intravitreal ranibizumab combined with retinal laser photocoagulation therapy as C group，followed by the preoperative observation of the best corrected visual acuity (BCVA)，slit lamp，fundus and intraocular pressure examination，fundus fluorescein angiography (FFA)，optical coherence tomography (OCT).One day after the surgery，BCVA，slit lamp and intraocular pressure examination were conducted，and 1 month，2 months，3 months after the surgery，observation of BCVA，slit lamp，fundus and intraocular pressure examination were performed.Then，OCT was used to determine the status of macular edema.And finally，BCVA and central macular thickness (CMT) in the three groups were statistically analyzed by observing the above indicators.Results　The BCVA at 1 month，2 months，and 3 months after treatment was higher than before treatment in all three groups，and the differences were statistically significant (all P<0.05).The BCVA of A group was 0.26±0.14 and 0.26±0.14 at 2 and 3 months after treatment，respectively,which was significantly better than that of B group (0.39±0.10 and 0.40±0.10) (all P<0.05).At 3 months after treatment，the BCVA in C group was 0.14±0.11，which was significantly higher than that in A group (0.26±0.14) (P<0.05).The BCVA of C group was 0.30±0.13，0.20±0.12，0.14±0.11 at 1 month，2 months and 3 months after treatment，respectively,which was better than that of B group (0.43±0.10，0.39±0.10，0.40±0.10)，and the differences were statistically significant (all P<0.05).The postoperative CMT was significantly reduced when compared with preoperation in all three groups (all P<0.05).The CMT at 1 month，2 months and 3 months after treatment in C group was (318.85±71.48)μm，(287.15±56.71) μm and (255.05±60.90)μm，respectively，which was better than that in A group ［(347.00±67.59)μm (305.10±47.44)μm and (282.40±36.26)μm］，and B group ［ (417.05±63.94)μm，(394.80±57.18)μm，and (375.90±55.10)μm］，with significant differences (all P<0.05).At 2 months and 3 months after treatment，CMT in A group was better than that in B group，and the difference was statistically significant(P<0.05).Conclusion　The efficacy of retinal laser photocoagulation combined with intravitreal ranibizumab in the treatment of BRVO macular edema is better than simple retinal laser photocoagulation and simple intravitreal ranibizumab.

参考文献/References:

［1］　NOMA H，MIMURA T，YASUDA K，NAKAGAWA H，MOTOHASHI R，KOTAKEL O，et al.Intravitreal ranibizumab and aqueous humor factors/cytokines in major and macular branch retinal vein occlusion［J］.Ophthalmologica，2016，235（3）：203-207.
［2］　SON Y，LEE S，PARK J.Measurement of lamina and prelaminar thicknesses of both eyes in patients with unilateral branch retinal vein occlusion［J］.Graefes Arch Clin Exp Ophthalmol，2017，255（5）：503-508.
［3］　LIM LL，CHEUNG N，WANG JJ，ISLAM FM，MITCHELL P，SAW SM，et al.Prevalence and risk factors of retinal vein occlusion in an Asian population［J］.Br J Ophthalmol，2008，92（10）：1316-1319.
［4］　LIU W，XU L，JONAS JB.Vein occlusion in Chinese subjects［J］.Ophthalmology，2007，114（9）：1795-1796.
［5］　KLEIN R，MOSS SE，MEUER SM，KLEIN BE.The 15-year cumulative incidence of retinal vein occlusion：the Beaver Dam Eye Study［J］.Arch Ophthalmol，2008，126（4）：513-518.
［6］　CUGATI S，WANG JJ，ROCHTCHINA E，MITCHELL P.Ten-year incidence of retinal vein occlusion in an older population：the Blue Mountains Eye Study［J］.Arch Ophthalmol，2006，124（5）：726-732.
［7］　HO JD，TSAI CY，LIOU SW，TSAI RJ，LIN HC.Seasonal variations in the occurrence of retinal vein occlusion：a five-year nationwide population-based study from Taiwan［J］.Am J Ophthalmol，2008，145（4）：722-728.
［8］　BUEHL W，SCHMIDT-ERFURTH A.Treatment of branch retinal vein occlusion［J］.Exp Rev Ophthalmol，2009，4（6）：661-669.
［9］　MAO XB，ZHAO JL，YOU ZP.The efficacy of early multiwavelength laser for retinal branch vein occlusions［J］.Guangdong Med J，2013，34（17）：2679-2681.
毛新帮，赵菊莲，游志鹏.早期多波长激光治疗视网膜分支静脉阻塞的疗效［J］.广东医学，2013，34（17）：2679-2681.
［10］　ZHENG Y，SHA XY，SONG L.The efficacy of subthreshold micropulse 577nm laser for macular edema secondary to branch retinal vein occlusion［J］.Chin J Pract Ophthalmol，2016，34（5）：439-442.
郑瑜，沙翔垠，宋莉.577nm阈下微脉冲激光治疗视网膜分支静脉阻塞继发黄斑水肿疗效观察［J］.中国实用眼科杂志，2016，34（5）：439-442.
［11］　LI YR.Curative effect of small dose of triamcinolone acetonide in vitreous body cavity injection treatment on retinal vein occlusion macular edema［J］.Xinxiang Med Univ，2016，33 （8）：695-697.
李玉茹.小剂量曲安奈德玻璃体腔注射治疗静脉阻塞黄斑水肿疗效观察［J］.新乡医学院学报，2016，33（8）：695-697.
［12］　ZHOU J，WANG HB，WANG WT.Efficacy of intravitreal injection of ranibizumab for retinal vein occlusion［J］.Rec Adv Ophthalmol，2016，36（1）：70-73.
周洁，王宏彬，王文婷.雷珠单抗治疗视网膜静脉阻塞的临床研究［J］.眼科新进展，2016，36（1）：70-73.
［13］　ZHOU S，XIA WT，LIU RJ，PENG SY，LIU DM.Applications and advances in visual function measured by microperimetry［J］.Rec Adv Ophthalmol，2015，35（3）：293-297.
周姝，夏文涛，刘瑞珏，彭书雅，刘冬梅.微视野检查评定视觉功能的临床应用研究进展［J］.眼科新进展，2015，35（3）：293-297.

相似文献/References:

[1]李国兴 韩丽英.曲安奈德玻璃体腔注射治疗黄斑水肿[J].眼科新进展,2008,28(9):000.
[2]周正申 孙静芬.白内障超声乳化术后黄斑区光学相干断层扫描观察[J].眼科新进展,2013,33(2):000.
[3]刘广峰 蔺洁 范颖 顾铮 高新晓 朱岩 孟忻 王华 贾宇颂 付秀稳 汪军.非增生型糖尿病视网膜病变黄斑水肿患者黄斑区谱域光学相干断层扫描中高反射信号的特征分析[J].眼科新进展,2013,33(4):000.
[4]鲁丹 王康 王艳玲 林鹏耀 李茜 李明铭.后Tenon囊下注射曲安奈德辅助全视网膜光凝治疗糖尿病视网膜病变[J].眼科新进展,2013,33(5):000.
[5]陆秉文 吴星伟.视网膜静脉阻塞黄斑水肿患者玻璃体内注射ranibi-zumab后视野变化[J].眼科新进展,2013,33(12):000.
[6]徐斌 戴奕娟 梁丽 杨露. 传统格栅样激光与577nm黄色微脉冲激光光凝治疗黄斑水肿疗效对比[J].眼科新进展,2014,34(2):181.
[7]陈素芳 曾莉 邵毅. 非诺贝特在糖尿病视网膜病变中的应用进展[J].眼科新进展,2014,34(3):283.
[8]肖昂,周琼.Aflibercept治疗湿性AMD和黄斑水肿的相关研究现状[J].眼科新进展,2014,34(6):598.[doi:10.13389/j.cnki.rao.2014.0165]
[9]魏光杰,何佃菊.532nm绿激光格栅样光凝联合球内注药治疗糖尿病视网膜病变黄斑水肿[J].眼科新进展,2014,34(8):779.[doi:10.13389/j.cnki.rao.2014.0215]
　WEI Guang-Jie,HE Dian-Ju.532 run green grid laser photocoagulation combined with intravitreal Avastin injection for diabetic retinopathy macular edema[J].Recent Advances in Ophthalmology,2014,34(4):779.[doi:10.13389/j.cnki.rao.2014.0215]
[10]金昱,石安娜,刘淼. 玻璃体内注射雷珠单抗（Ranibizumab）治疗视网膜静脉阻塞继发黄斑水肿[J].眼科新进展,2014,34(9):855.[doi:10.13389/j.cnki.rao.2014.0236]
[11]张祺 冯劼 李培凤 金翼.Lucentis联合氪黄激光治疗视网膜分支静脉阻塞黄斑水肿的疗效观察[J].眼科新进展,2013,33(12):000.
[12]曹婷婷,陈桂芬,范玉香,等.视网膜分支静脉阻塞合并黄斑水肿不同治疗方法的疗效观察[J].眼科新进展,2014,34(8):772.[doi:10.13389/j.cnki.rao.2014.0213]
　CAO Ting-Ting,CHEN Gui-Fen,FAN Yu-Xiang,et al.Clinical observation in different treatment methods of branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2014,34(4):772.[doi:10.13389/j.cnki.rao.2014.0213]
[13]傅维娜,陈梅珠,王云鹏. Lucentis联合视网膜光凝治疗视网膜分支静脉阻塞继发黄斑水肿[J].眼科新进展,2015,35(3):270.[doi:10.13389/j.cnki.rao.2015.0072]
　FU Wei-Na,CHEN Mei-Zhu,WANG Yun-Peng. Intravitreal injection with lucentis combined with local retinal photocoagulation for macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2015,35(4):270.[doi:10.13389/j.cnki.rao.2015.0072]
[14]李仕永,高瑞莹,陈晖.雷珠单抗联合氩激光视网膜光凝治疗不同时期的视网膜分支静脉阻塞所致黄斑水肿的疗效[J].眼科新进展,2016,36(12):1161.[doi:10.13389/j.cnki.rao.2016.0309]
　LI Shi-Yong,GAO Rui-Ying,CHEN Hui.Effects of ranibizumab ( Lucentis) intravitreal injection combined with retinal argon laser photocoagulation on macular edema secondary to different period of branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(4):1161.[doi:10.13389/j.cnki.rao.2016.0309]
[15]刘广峰,洪婷婷,苗森,等.玻璃体内注射康柏西普与黄斑区光凝治疗视网膜分支静脉阻塞继发非缺血性黄斑水肿的临床对照研究[J].眼科新进展,2017,37(7):658.[doi:10.13389/j.cnki.rao.2017.0167]
　LIU Guang-Feng,HONG Ting-Ting,MIAO Sen,et al.Comparison of intravitreal injection of conbercept and macular photocoagulation for non-ischemic macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2017,37(4):658.[doi:10.13389/j.cnki.rao.2017.0167]
[16]石蕊,肖云芳,王峰,等.糖尿病合并视网膜分支静脉阻塞患者继发黄斑水肿后视力损伤程度及危险因素[J].眼科新进展,2017,37(12):1139.[doi:10.13389/j.cnki.rao.2017.0287]
　SHI Rui,XIAO Yun-Fang,WANG Feng,et al.Vision impairment following macular edema secondary to diabetes combined with branch retinal vein occlusion and its potential risk factors[J].Recent Advances in Ophthalmology,2017,37(4):1139.[doi:10.13389/j.cnki.rao.2017.0287]
[17]赵芃芃,秦梅.视网膜分支静脉阻塞治疗研究现状[J].眼科新进展,2018,38(5):485.[doi:10.13389/j.cnki.rao.2018.0114]
　ZHAO Peng-Peng,QIN Mei.Treatment research status of branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2018,38(4):485.[doi:10.13389/j.cnki.rao.2018.0114]
[18]林国乔,郑德志,陈伟奇.康柏西普治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿的临床研究[J].眼科新进展,2018,38(11):1055.[doi:10.13389/j.cnki.rao.2018.0248]
　LIN Guo-Qiao,ZHENG De-Zhi,CHEN Wei-Qi.Clinical outcomes of intravitreal Conbercept injection for macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2018,38(4):1055.[doi:10.13389/j.cnki.rao.2018.0248]
[19]杨大勇,李琳.雷珠单抗联合激光光凝术治疗视网膜分支静脉阻塞（BRVO）继发黄斑水肿疗效观察[J].眼科新进展,2019,39(4):369.[doi:10.13389/j.cnki.rao.2019.0084]
　YANG Da-Yong,LI Lin.Ranibizumab combined with laser photocoagulation in the treatment of patients with macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2019,39(4):369.[doi:10.13389/j.cnki.rao.2019.0084]
[20]尹小芳,叶祖科,汤秀容,等.玻璃体内注射雷珠单抗后视网膜分支静脉阻塞性黄斑水肿复发的危险因素分析[J].眼科新进展,2020,40(1):046.[doi:10.13389/j.cnki.rao.2020.0011]
　YIN Xiaofang,YE Zuke,TANG Xiurong,et al.Risk factors for recurrence of macular edema associated with branch retinal vein occlusions after intravitreal injection of Ranibizumab treatment[J].Recent Advances in Ophthalmology,2020,40(4):046.[doi:10.13389/j.cnki.rao.2020.0011]

备注/Memo

备注/Memo:
辽宁省科技厅项目基金资助（编号：2015020361）
更新日期/Last Update: 2018-04-02